Right ventricular hemodynamic support with the PROTEKDuo Cannula. Initial experience from the tandemheart experiences and methods (THEME) registry category: Miscellaneous
Recommended Citation
O'Neill B, Ramzy D, Coletti A, Chetcuti S, Ragosta M, Bermudez C, Joyce D, Alaswad K. Right ventricular hemodynamic support with the PROTEKDuo Cannula. Initial experience from the tandemheart experiences and methods (THEME) registry category: Miscellaneous. Catheter Cardiovasc Interventions. 2018;91:S116.
Document Type
Conference Proceeding
Publication Date
2018
Publication Title
Catheter Cardiovasc Interventions
Abstract
Background: Right ventricular (RV) failure is associated withincreased morbidity and mortality. Surgical treatment options are limited when medical therapy fails. We present the initial findings of percutaneous RV support utilizing thePROTEKDuo veno-venous cannula from the THEME registryMethods: The THEME registry is a multi-center, prospective observational registry describing use of TandemLife products in a realworld setting. The PROTEKDuo is a dual lumen cannula intended for both venous drainage and reinfusion of blood via an internal jugular vein during extracorporeal life support procedures. The PROTEKDuohas been used for RV support when placed in RA-PA configuration. Results: Thirty consecutive patients received the PROTEKDuo and TandemHeart Pump for RV failure. Mean age was 54±18 yrs and 67% were male. Co-morbidities included coronary artery disease 43.3%, hx of coronary artery bypass grafting 10.0%, congestive heart failure 56.7%, and chronic obstructive pulmonary disease 6.7%. Baseline number of pressors and inotropes were 0 (10.0%), 1 (20.0%), 2 (33.3%), 3 (20.0%), or 4+ (16.7%). Reasons for use included cardiogenic shock (40%) and peri/post-op Left Ventricular Assist Device (46.7%). Device insertion was successful in 30/30 (100%) cases and mean support time was 8.7±6.4 days. Survival to removal was 76.7% with similar rates for shock vs. non-shock (Figure 1). Overall survival to 30-days was 72.4%. Conclusion: ThePROTEKDuo is a viable percutaneous option for patients with RV failure. Rates of successful insertion are high and initial survival to removal and 30-day survival are similar. (Figure Presented).
Volume
91
First Page
S116